NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $16.03 -0.90 (-5.32%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$16.03 0.00 (0.00%) As of 09/18/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$15.92▼$17.7550-Day Range$5.53▼$16.9352-Week Range$5.50▼$24.17Volume841,465 shsAverage Volume1.23 million shsMarket Capitalization$455.62 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA. Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions. Its research programs have included treatments for ornithine transcarbamylase deficiency and cystic fibrosis, as well as vaccines and vaccine technology based on self-amplifying mRNA. The company has also pursued development and commercialization partnerships, including collaborations involving its rare-disease and vaccine programs. Headquartered in San Diego, California, Arcturus serves global biotechnology and pharmaceutical markets through its research programs and partnerships. The company was founded in 2013 and is led by Joseph Payne, who serves as president and chief executive officer. Arcturus’ work centers on advancing RNA medicines from discovery and preclinical research through clinical development and potential commercialization.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 341st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingArcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $23.00, representing about 43.5% upside from its current price of $16.03.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($3.48) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted26.10% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 6.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth.Read more about Arcturus Therapeutics' dividend. News and Social Media2.8 / 5News Sentiment0.53 News SentimentArcturus Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest18 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesArcturus Therapeutics Holdings Inc Hosts Virtual Presentation On ARCT-810 Phase 2 Clinical Program And Provides Update On mRNA Liver Therapeutics PlatformSeptember 18 at 6:25 PM | marketscreener.comMArcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics PlatformSeptember 18 at 10:00 AM | businesswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 19 at 1:00 AM | Porter & Company (Ad)Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $23.00 Consensus PT from AnalystsSeptember 16 at 3:44 AM | americanbankingnews.comArcturus Therapeutics Holdings consensus price target increased by 14.69% to $22.75September 15, 2026 | msn.comArcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comArcturus, Moderna fall after BioNTech's cancer vaccine setbackAugust 28, 2026 | seekingalpha.commRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode ...August 26, 2026 | finance.yahoo.comSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 at the beginning of 2026. Since then, ARCT stock has increased by 161.5% and is now trading at $16.03. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its earnings results on Friday, August, 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.16. The biotechnology company had revenue of $2.96 million for the quarter, compared to analysts' expectations of $3.11 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 46.54% and a negative net margin of 317.62%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Top institutional shareholders of Arcturus Therapeutics include BlackRock Inc. (9.20%), Hennion & Walsh Asset Management Inc. (1.22%), Heartland Advisors Inc. (0.77%) and Bank of New York Mellon Corp (0.28%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2026Today9/19/2026Status update9/23/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ARCT's financial health is in the Green zone, according to TradeSmith. ARCT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees111Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$23.00 High Price Target$41.00 Low Price Target$9.00 Potential Upside/Downside+43.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-317.62% Pretax Margin-317.64% Return on Equity-46.54% Return on Assets-36.46% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual Sales$18.72 million Price / Sales24.33 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book2.13Miscellaneous Outstanding Shares28,423,000Free Float23,364,000Market Cap$455.62 million OptionableOptionable Beta2.48 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ARCT) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
